Joel H. Kaufman
2021
In 2021, Joel H. Kaufman earned a total compensation of $147.3K as Former Chief Business Officer at Navidea Biopharmaceuticals, a 55% decrease compared to previous year.
Compensation breakdown
| Option Awards | $46,962 |
|---|---|
| Salary | $81,458 |
| Other | $18,845 |
| Total | $147,265 |
Kaufman received $81.5K in salary, accounting for 55% of the total pay in 2021.
Kaufman also received $47K in option awards and $18.8K in other compensation.
Rankings
In 2021, Joel H. Kaufman's compensation ranked 12,125th out of 12,397 executives tracked by ExecPay. In other words, Kaufman earned more than 2.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,125 out of 12,397 | 2nd |
Division Manufacturing | 5,365 out of 5,492 | 2nd |
Major group Chemicals And Allied Products | 2,328 out of 2,367 | 2nd |
Industry group Drugs | 2,055 out of 2,090 | 2nd |
Industry In Vitro and In Vivo Diagnostic Substances | 60 out of 61 | 2nd |
Source: SEC filing on October 24, 2022.
Kaufman's colleagues
We found four more compensation records of executives who worked with Joel H. Kaufman at Navidea Biopharmaceuticals in 2021.
2021
Jed Latkin
Navidea Biopharmaceuticals
Chief Executive Officer
2021
Michael Rosol
Navidea Biopharmaceuticals
Chief Medical Officer
2021
Erika Eves
Navidea Biopharmaceuticals
Vice President, Finance & Administration
2021
Michel Mikhail
Navidea Biopharmaceuticals
Chief Regulatory Officer
News
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019